According to a study in the Aug. 2 issue of The Lancet, old people who receive flu vaccines may remain vulnerable to pneumonia
NEW YORK According to a study in the Aug. 2 issue of The Lancet, old people who receive flu vaccines may remain vulnerable to pneumonia.
Contradicting the previous assumption that flu vaccines were effective among all elderly age groups, the research shows that they may only protect healthy seniors in lower age groups as opposed to older, less healthy seniors.
The study, led by a researcher from Seattle’s Group Health Center for Health Studies, examined data on 1,173 people aged 65 to 94 who had developed pneumonia and 2,346 who did not develop it. Both groups had similar flu vaccination rates.
Gestational diabetes results in increased risk for Type 2 diabetes
NEW YORK Gestational diabetes greatly increases a woman’s risk of developing Type 2 diabetes later on in life, a new study confirms, according to Reuters.
Gestational diabetes is a known risk factor for Type 2 diabetes. Denice Feig of the University of Toronto and her team looked at 633,449 women who gave birth in Toronto between 1995 and 2002. A total of 21,823 (3.3 percent) of the women were diagnosed with gestational diabetes.
While just 2 percent of the women who didn’t have gestational diabetes went on to develop Type 2 diabetes during the 9-year follow-up period, 19 percent of those with gestational diabetes did, the researchers found.
Moreover, they say the strongest risk factor for Type 2 diabetes was gestational diabetes, which increased risk more than 37-fold.
Russian antihistamine appears effective against Alzheimer’s
NEW YORK A study that lasted a year and a half has found that an antihistamine developed in the former Soviet Union may be able to stabilize Alzheimer’s disease.
The study, presented at the International Conference on Alzheimer’s Disease, found that the drug Dimebon could stabilize the disease for at least the time of the study. Researchers tested the drug against a placebo in 183 patients in Russia who had mild to moderate Alzheimer’s.
Conditions of patients who received the placebo deteriorated, while those of the people who received Dimebon improved or deteriorated only slightly.